Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vertos Medical Inc. on the transaction. Stryker (NYSE: SYK), a global leader in medical technologies, announced a definitive agreement to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction. BioMap announced a collaboration with Sanofi, to co-develop advanced AI modules for biotherapeutic drug discovery leveraging BioMap’s...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Inscopix on the deal. Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the deal. ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
